Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Viracta Therapeutics to Host R&D Day on October 4, 2023

GlobeNewswire September 5, 2023

Viracta Therapeutics Announces New Employment Inducement Grant

GlobeNewswire August 18, 2023

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

GlobeNewswire August 8, 2023

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

GlobeNewswire August 7, 2023

Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

GlobeNewswire June 28, 2023

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 11, 2023

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

GlobeNewswire May 8, 2023

Viracta Therapeutics Announces Departure of Chief Medical Officer

GlobeNewswire May 2, 2023

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

GlobeNewswire April 19, 2023

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

GlobeNewswire March 13, 2023

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

GlobeNewswire March 8, 2023

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

GlobeNewswire January 19, 2023

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

GlobeNewswire January 8, 2023

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

GlobeNewswire November 30, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

GlobeNewswire November 21, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

GlobeNewswire November 14, 2022

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

GlobeNewswire November 10, 2022